Atlas Trials

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Clinical trial NCT05127382 · UNKNOWN

Trial details

NCT number
NCT05127382
Sponsor
Hellenic Cooperative Oncology Group
Status
UNKNOWN
Study type
OBSERVATIONAL
Lung Cancer Non-small Cell Stage IV
Start date
2020-02-01
Primary completion
2024-12-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.